2. Signaling Pathways
  3. Epigenetics
  4. SF3B1
  5. SF3B1 Ligand

SF3B1 Ligand

SF3B1 Ligands (2):

Cat. No. Product Name Effect Purity
  • HY-181421
    WX-02-43
    		Ligand 99.49%
    WX-02-43 is a weak covalent inhibitor of SF3B1, and is the (1S,3R) enantiomer of WX-02-23 (HY-168534). WX-02-43 cannot effectively covalently modify the C258 site in the DNA-binding domain of FOXA1, and its inhibitory activity against SF3B1 is also weaker than that of WX-02-23. WX-02-43 serves as a negative control probe that fails to remodel the chromatin binding pattern and transcriptional activity of FOXA1. WX-02-43 can be used in studies on cancers such as prostate cancer to verify the specific effects of WX-02-23 on FOXA1 and SF3B1 targets.
  • HY-120907
    Sudemycin E
    		Ligand
    Sudemycin E is an analog of FR901464 (HY-16212). Sudemycin E can induce reversible changes in alternative splicing and abnormalities in chromatin modifications by binding to SF3B1, a component of the U2 small nuclear ribonucleoprotein (snRNP), thereby leading to the death of cancer cells. Sudemycin E has anti-tumor activity and can be used in tumor research.